Significance of Liquid Biopsy Containing Circulating Tumor DNA (ctDNA) Analysis for Evaluation and Management of Metastatic Cancer

Journal Title: Diseases & Research - Year 2023, Vol 3, Issue 1

Abstract

According to the GLOBOCAN 2020 data from WHO, nearly 10 million deaths took place due to cancer thus, cancer became a leading cause of death all over the world. The most common cancer are breast cancer, lung cancer, colon cancer, prostate cancer, and pancreatic cancer. In the last few decades, Tissue Biopsy was considered the major approach to finding a confirmed diagnosis of particular cancer but due to the invasive process, it has become difficult for the clinician to ask for frequent tissue biopsies for the monitoring targeted treatment of the patients and thus clinicians generally assume the potency of the drugs without doing any biopsy analysis and thus there is an increase in the mortality of cancer patients. However, the liquid biopsy technique has changed this protocol of such treatment and greatly revolutionized the field of Clinical Oncology. Liquid biopsy ensures better-targeted treatment and many times help to give a complete cure. Liquid Biopsy is a non-invasive standard procedure to identify and prognose the tumor markers from circulating blood samples. It also offers the ease of sampling continuous screening, monitoring devices, therapeutic regimens, etc. Liquid Biopsy is composed of several components such as Circulating Tumor Cells (CTCs), free Circulating Tumor DNA (ctDNA), exosomes, vesicles, and platelets. The liquid biopsy includes body fluids such as blood, saliva, plasma, cerebrospinal fluid, and urine. Circulating Tumor DNA (ctDNA) in the blood sample of metastatic cancer patients has become the most critical technology to evaluate the progression of metastasis and give a precise treatment for many cancers. ctDNA analysis provides insight into the molecular profiling and biological characteristics of several tumors. This review is mainly aimed at highlighting the important technological development in ctDNA analysis and also to provide the significance of it in monitoring metastatic cancers and providing the best treatment to cure cancer.

Authors and Affiliations

Mansi Gupta, Pravin Potdar

Keywords

Related Articles

Primary Extramedullary Plasmacytoma of the Kidney: A Case Report and Literature Review

Extramedullary plasmacytomas (EMPs) usually occur in the upper respiratory tract, the occurrence in the kidney is extremely rare. The present study reported a case of primary renal plasmacytoma in a 46-year-old male pati...

Gut Microbiota is A Crucial Bridge Mediating the Pharmacological Effect of Labiatae Traditional Chinese Medicine

Labiatae, a family of the dicotyledonous plants, has attracted extensive interest because of its wide application in foods, drugs and cosmetics. According to the National Census of Chinese Medicine Resources, Labiatae co...

Recurrent Middle Ear Cancer: Case Report

Background: Middle ear cancer is clinically uncommon, representing approximately 1.5% of ear malignancies and 0.03% to 0.06% of all cancers. Recurrent cases of middle ear cancer are particularly rare. This report discuss...

Emergence, Mechanism of Action, Clinical Applications and Challenges of Nanomedicine for Tumor Therapy

With the increase in cancer cases globally, researchers have tried various methods to treat cancer. The study of nanomedicine, a novel drug form, has gained popularity in the medical community. Nanomedicine is a signific...

Clinical Applications of Recombinant Human Granulocyte Colony-Stimulating Factor in Reproductive Medicine: Expert Consensus

Recombinant human granulocyte colony-stimulating factor (rhG-CSF) is primarily indicated for neutropenia caused by various etiologies in clinical practice. Recently, it has been shown to have some therapeutic effects and...

Download PDF file
  • EP ID EP740142
  • DOI 10.54457/DR.202301003
  • Views 67
  • Downloads 0

How To Cite

Mansi Gupta, Pravin Potdar (2023). Significance of Liquid Biopsy Containing Circulating Tumor DNA (ctDNA) Analysis for Evaluation and Management of Metastatic Cancer. Diseases & Research, 3(1), -. https://europub.co.uk./articles/-A-740142